Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lonza to make antibody-drug conjugates for a major client
by Aayushi Pratap
October 27, 2024
| A version of this story appeared in
Volume 102, Issue 34
Lonza has extended its antibody-drug conjugate (ADC) manufacturing contract with a major biopharmaceutical customer, according to a press statement, which does not name the client. Lonza says that as part of the agreement it will build an 800 m2 bioconjugation suite at its complex in Visp, Switzerland, to manufacture ADCs for “hard-to-treat cancers.” The Swiss drug services firm says it expects the facility to open in 2027 and to generate about 100 new jobs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X